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SUMMARY
Regenerative medicine is emerging as a novel field in organ transplanta-
tion. In September 2019, the European Cell Therapy and Organ Regenera-
tion Section (ECTORS) of the European Society for Organ Transplantation
(ESOT) held its first meeting to discuss the state-of-the-art of regenerative
medicine in organ transplantation. The present article highlights the key
areas of interest and major advances in this multidisciplinary field in organ
regeneration and discusses its implications for the future of organ trans-
plantation.
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Introduction
Current treatment options for end-stage organ disease
include support of organ function through dialysis, res-
piratory devices or ventricular pumps, lifestyle changes
to slow down disease progression, and eventually trans-
plantation. The impressive advance in knowledge of
genetic editing and cellular reprogramming over the
past period has led to the idea of boosting endogenous
regeneration or supply de novo generated cells and tis-
sues as an alternative to transplantation. However, many
biological, technical and ethical challenges must be
addressed before improvement of organ function
through reparative therapies can be realized. To that
end, the European Cell Therapy and Organ Regenera-
tion Section (ECTORS) was established in 2018 within
the European Society for Organ Transplantation
(ESOT). This section finds its origin in the former Mes-
enchymal stromal cell in Solid Organ Transplantation
(MiSOT) study group [1-3], but also includes experts
on organ machine perfusion, pluripotent stem cells
including human embryonic stem cells and induced
pluripotent stem cells (iPSC), and organoids. The aim
of ECTORS is to advance the knowledge of organ
regeneration through bringing together physicians and
basic scientists from the regenerative medicine and
transplantation fields.
In this article, we discuss the state of the art and
recent advances in organ regenerative medicine research.
This includes repair of transplant organs before and
after transplantation, and of diseased organs in patients
with end-stage organ failure.
Organ regeneration
Organ regeneration ultimately involves the reinstitu-
tion of multiple types of cells and supportive matrix
with the aim to restore integrity and function of dis-
eased organs. If successful, organ regeneration could
eventually make organ transplantation obsolete.
Organ regeneration can be approached from different
angles, depending on the status of the injured organ
and the tools available. One approach is to make
use of the intrinsic regenerative potential of organs
and activate endogenous progenitor cells through
pharmacological or cellular intervention or through
manipulation of organ physiology. Experiments in
this direction are ongoing and promising tools are
under development, including machine perfusion and
mesenchymal stromal cell (MSC) therapy that may
boost organ regeneration. Nevertheless, many hurdles
have to be overcome, including ethical, financial,
logistic and mechanistic challenges, before these tools
can be applied for effective organ regeneration.
Another approach is to build organs or part of
organs from scratch. While it is highly unlikely such
techniques will be feasible in the short-term, this
concept brings with it an immense potential to
regenerate organs of all ages and in all developmen-
tal and disease states.
Organ machine perfusion
In recent years, progress has been made with preserva-
tion of transplant organs on hypothermic machine
perfusion [4,5]. Indeed, in the Netherlands and in the
UK, hypothermic machine preservation has become
standard practice for all kidneys from deceased donors.
The benefit of oxygenation of kidneys on hypothermic
machine perfusion for kidney function has been
demonstrated in seminal studies [6,7]. A multicentre
randomized trial in heart transplant patients demon-
strated that patient and heart survival after warm per-
fusion of heart transplants was noninferior to cold
storage and offers possibilities to assess the metabolic
status of heart transplants [8]. To develop machine
perfusion into a technology that does not only pre-
serve but also regenerates organs, further adaptations
are required, including normothermia. Normothermic
machine perfusion (NMP) is designed to preserve
organs under physiological conditions allowing the
restoration of cellular metabolism and replenishment
of ATP [9-11]. It also has the potential as a platform
for assessment of the donor organ before
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transplantation and for pretransplant therapeutic inter-
ventions to enhance organ quality [12]. The molecular
mechanisms underlying NMP involve oxidative phos-
phorylation, which is amongst the pathways most sig-
nificantly up regulated during NMP. NMP furthermore
leads to increased expression of erythropoietin and
haemeoxygenase-1 and, in addition, a number of
immunological pathways including TNFa signalling via
NFᴋB are also significantly up regulated. The inclusion
of a cytosorb column into the perfusion circuit to
adsorb cytokines and chemokines may be used to
reduce the level of pro-inflammatory cytokines [13].
Other inflammatory pathways up regulated during
NMP, such as the JAK/STAT pathway, are associated
with ischaemic conditioning [14]. It may be through
these processes that NMP protects against ischaemia
reperfusion injury in kidney transplantation.
Also within the field of liver transplantation, the
implementation of machine perfusion is advancing.
Conventional static cold storage is insufficient for the
preservation of high-risk livers and does not allow for
the evaluation of residual functionality of the liver graft.
By applying heart-lung machine technology to the iso-
lated organ, liver machine perfusion allows for better
preservation and functional evaluation of the liver [15].
Liver machine perfusion can either replace conventional
storage [16] or can resuscitate grafts previously pre-
served in a conventional manner [17]. Additionally, by
repeatedly sampling the perfusate and bile produced
during machine perfusion and measuring simple serum
biomarkers, it is possible to assess the functionality of a
graft and to predict the risk of post-transplant compli-
cations [18].
Regeneration cannot be achieved during a few hours
of machine perfusion, but regenerative processes can be
initiated ex vivo while organs are on machine perfusion.
Preservation of organs through machine perfusion pro-
vides an excellent opportunity to apply regenerative
therapies directly to the organs, including cellular and
molecular interventions. The application of microvesi-
cles or exosomes from regenerative cells such as MSC is
an appealing setting to be further investigated [19]. Fur-
thermore, the modulation of the expression of micro-
RNAs with the aim to induce repair may also represent
a yet unexplored approach to donor organ treatment
outside the donor.
Mesenchymal stromal cell therapies
Mesenchymal stromal cell has immunomodulatory and
tissue regenerative properties and therefore make them
an attractive therapeutic candidate within organ trans-
plantation. Over the last decade, a number of studies
have investigated the intravenous administration of
autologous MSC after human kidney transplantation
and demonstrated safety, feasibility and an indication
for immunosuppressive capacities of autologous bone
marrow derived MSC [20,21]. It appears that the tim-
ing of MSC treatment and the concurrent immuno-
suppressive medication influences the effects of MSC
[22,23]. It has for instance been shown that pretrans-
plant but not post-transplant administration of MSC is
effective in prolonging allograft survival in murine
models and there is data suggesting that immunosup-
pressive drug such as tacrolimus, mycophenolic acid
and rapamycin differentially affect MSC proliferation
and immunomodulatory capacity [22,24,25]. With the
first exploratory studies completed over 7 years ago,
long-term safety profiles of MSC treatment are avail-
able. To date, there is currently no evidence for
adverse effects in kidney transplant patients long after
MSC administration [26]. In addition, autologous
MSC therapy promoted a sustained and long-lasting
pro-tolerogenic immune environment, particularly
remarkable in one kidney transplant patient. This
patient was successfully weaned off immunosuppressive
drugs and is now almost two 2 years free from rejec-
tion with optimal kidney allograft function [27]. Treat-
ment with autologous bone marrow MSC in kidney
recipients is now moving from Phase I to Phase II tri-
als. A currently ongoing phase 2 study is testing the
hypothesis that MSC in combination with everolimus
immunosuppression facilitates withdrawal of the cal-
cineurin inhibitor tacrolimus, reduce fibrosis and
decrease the incidence of opportunistic infections com-
pared to standard tacrolimus medication [28]. The pri-
mary end-point of this study is fibrosis measured by
quantitative Sirius Red scoring at 6 months after trans-
plantation. Results will provide information on
whether MSC in combination with everolimus allows
graft survival with preservation of renal structure and
function.
Allogeneic MSCs offer an alternative cellular thera-
peutic strategy to autologous therapies. Allogeneic MSC
can be expanded on a large scale and are amenable to
cryopreservation. A number of commercial organiza-
tions are actively developing allogeneic MSC-based
products as ‘off-the-shelf’ cellular therapies. Such a pro-
duct would be available as required and be used by
those treatment centres that lack a dedicated GMP cel-
lular-production facility. However, there is evidence that
allogeneic MSC can elicit an anti-MSC immune
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response [29], which may cross-react with the donor
kidney and increase the incidence of rejection and
impact allograft survival in the long term. In a recent
Phase I study, a single dose of 1.5–3 9 106/kg
unmatched third party MSC were infused 3  2 days
after transplantation. Four out of 10 patients developed
de novo donor-specific antibodies (dnDSA) against the
MSC, one of which was also directed against the kidney
graft. Renal function remained stable in patients during
the study period leaving clinical relevance of the dnDSA
unclear [30]. The Neptune study was set op to investi-
gate the effect of third party allogeneic MSC after kid-
ney transplantation with the aim to lower calcineurin
inhibitor levels. To minimize the chance of anti-donor
immune responses, a matching strategy was chosen to
prevent repeated mismatches between the allogeneic
MSC and the transplant kidney [31]. The results of this
study are expected in the near future.
MSC mechanism of action
While clinical studies to the effects of MSC in organ
transplant patients are ongoing, questions remain
regarding their mode of action. It has been demon-
strated that MSC interacts with a variety of immune
and progenitor cells through the secretion of growth
factors, cytokines and extracellular vesicles and induce
beneficial immunomodulatory and regenerative effects
[32,33]. It became clear some years ago, however, that
intravenously infused MSC largely accumulate in the
lungs due to size restriction of the pulmonary capillary
network and have a short lifespan [34]. In recent years,
important steps have been made in elucidating the
mechanism of action of MSC therapy after intravenous
infusion. It was demonstrated that during their brief
presence MSC instruct host immune cells to adapt a
regulatory function, and this effect persists after disap-
pearance of the administered cells [35-37]. These regu-
latory immune cells migrate to other sites, such as the
liver and lymph nodes but potentially also to sites of
inflammation, where they may control inflammatory
responses [38,39]. Thus, the short lifespan of MSC
does not preclude a beneficial immunomodulatory
effect of MSC in organ transplant patients. The impli-
cation of the short lifespan of MSC on their regenera-
tive effects is yet unclear, but during their brief
presence MSC may induce macrophages with regenera-
tive properties [40,41]. An alternative to intravenous
administration could be to deliver MSC directly to
transplant organs on machine perfusion via the arterial
flow.
Merging the fields of machine perfusion and
MSC therapy
The first reports on the ex vivo delivery of MSC to
porcine liver and kidney grafts have recently been pub-
lished. In the liver, administered MSC show a wide
range and patchy distribution [42] whereas in the kid-
ney MSC localize specifically to the glomeruli [43,44].
The distribution pattern of MSC in liver and kidney is
likely to depend on the size restriction of capillary net-
works in the organs, similar to the accumulation of
MSC in the capillaries of the lungs after intravenous
administration. This was demonstrated by arterial
administration of dead MSC to kidneys on machine
perfusion. While dead MSC are incapable of actively
adhering to surfaces, the resulting distribution pattern
was identical to that of living MSC [44]. When admin-
istering cells to organs on machine perfusion, it is
important to use perfusion conditions that not only
support the transplant organ, but also the administered
cells. It appears that machine perfusion fluid has an
effect on the adhesive properties of MSC in suspension,
but that it does not affect the secretion of trophic fac-
tors by MSC [45]. Whether loading of transplant
organs with MSC is beneficial for short-term and/or
long-term organ function after transplantation, or
whether other cell types at different doses would be
more efficient will have to be determined in future
studies.
Lessons learned from stem cell clinical trials
outside the field of organ transplantation
Cellular therapies are notoriously difficult to initiate,
in part due to regulatory requirements and the need
for clinical grade cell production facilities and associ-
ated costs. By learning from previously approved trials,
time and money might be saved and pitfalls related to
cell production, logistics, inclusion criteria and clinical
protocols avoided. While completed cell therapy trials
in the field of organ transplantation with published
results are relatively sparse, other fields have more
extensive experience with MSC therapies. In the field
of ischaemic heart disease, a number of trials have
been finalized [46,47] or are ongoing [48,49]. Such tri-
als teach us that it is advisable to keep the various
processes in trials as simple as possible and choose
clinically relevant inclusion criteria to increase clinical
success rate. It is important to constantly follow-up on
the regulation and collaborates with relevant partners
with expertise in cell production, clinical trial set up
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and regulatory aspects. When trials become more
advanced, partnering with a commercial party may offer
possibilities for progression towards efficacy testing and
eventually the implementation of cellular therapies as an
accessible treatment option for organ disease patients.
Corporate perspective on cell therapy
When cell therapy trials become larger and therapies
start moving from the experimental setting to the thera-
peutic setting, academic centres are generally insuffi-
ciently equipped and funded to continue the research
efforts without the help of a commercial partner. Ather-
sys, amongst other clinical-stage biotechnology compa-
nies to collaborate with the academic sector, has
developed a patented, allogeneic adult stem cell-derived
off-the-shelf product for indications in areas of neuro-
logical, cardiovascular and inflammatory and immune
disorders. Over the course of several years, the Athersys
product has been investigated in a preclinical cardiac
transplant model [50] and has been administered safely
to patients receiving a liver transplant [51]. Outside the
organ transplantation field, TiGenix-Takeda received
marketing approval in the European Union in 2018 for
the first allogeneic MSC product, and in the same year
Mesoblast announced the positive results of its open-la-
bel Phase III trial in steroid-refractory acute GvHD,
demonstrating that corporate involvement can bring
cellular therapies closer to the clinic.
Decellularization and recellularization
Organs that are in a severe state of degeneration are
unlikely to be responsive to reparative therapies through
machine perfusion and adult stem cell therapies. For
these organs, radical regenerative strategies are required.
Recently, effective protocols for porcine and human liv-
ers decellularization have been developed that consider-
able shorten the duration of decellularization by
increased pressure and flow without increased damage
to the extracellular matrix [52]. The development of
organ decellularization techniques has resulted in the
accumulation of knowledge on the generation of acellu-
lar scaffolds for application in regenerative medicine,
including for recellularization purposes. An interesting
initiative in this field is the heterotopic implantation of
decellularized hearts with the intent to allow the recipi-
ent body to repopulate the scaffold with endothelial and
stromal cell types [53]. Other advances in this field are
the generation of allogenic hydrogels for applications in
tissue engineering, including 3D bioprinting [54].
The emergence of organoids for regenerative
research
In recent years, considerable progress has been achieved
in creating organ-like structures known as organoids
from adult and pluripotent stem cells for virtually all
types of tissue [55]. Kidney organoids with a surprising
level of complexity can now be created within a few
weeks from an undefined clump of pluripotent stem
cells [56-59]. While initial work led to the generation of
kidney organoids resembling first-trimester kidney tissue
in structural organization and gene expression patterns,
recent advances in culture protocols are driving differ-
entiation further towards the second-trimester stadium
[60]. Furthermore, implantation of organoids and sub-
sequent vascularization in the host has been indicated
to steer kidney organoid differentiation towards more
maturity [61,62]. Importantly, it has been recently
shown that the implantation of kidney organoids for a
5 days period leads to the organization of endogenous
endothelial cells [60].
Other surrogates of organ-like microcultures are liver
organoids. These can be generated from Leucine rich
repeat-containing G protein-coupled receptor 5 (Lgr5+)
adult liver stem cells or from pluripotent stem cells and
resemble the original liver epithelial architecture
[63,64]. To implement the use of liver organoids for
liver repair, new techniques are being explored includ-
ing the use of decellularized liver to use as a scaffold for
repopulation by organoid-derived cells [65]. Further-
more, improvements in the large-scale expansion of
human liver organoids in oxygenated spinner flasks
bring the application of these cells for whole-size graft
repair in the clinical setting a step closer [66]. Advance-
ments in upscaling have also been made for drug
screening on cardiac organoids, where bioengineered
human cardiac organoids find use for high-throughput
testing of small molecules with pro-regenerative poten-
tial to stimulate cardiomyocyte proliferation [67] and
long-term expansion methodology for airway organoids
to allow disease modelling [68]. Other applications from
the field of bioengineering include the implementation
of organ-on-a-chip devices to promote kidney organoid
vascularization [69] or the application of extrusion-
based printing for the generation of kidney organoids
aiming to provide solutions for current issues related to
organoid inter-batch variability [70].
In the near term, organoids offer an unprecedented
opportunity in organ transplantation research, including
their application as models for studying organ disease, for
(personalized) drug testing or for studying organ
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development and physiology. In the future, it is antici-
pated that organoids will be applied as regenerative thera-
pies. In the field of organ transplantation, this implies
repair of aged and diseased transplant organs, and in the
treatment of end-stage organ disease patients with an aim
to repair organs and to delay or replace transplantation.
Ethical perspective
Developments in regenerative medicine raise many ethi-
cal issues including use of animal-testing in clinical
research, research using human embryonic stem cells,
foetal stems cells or discarded organs, issues with bio-
banking of ‘live’ material, informed consent for donation
and use, commercialization of human cell-derived prod-
ucts, as well as research integrity and communication
with the general public [71]. Human organoids may
prove to be a useful alternative to animal models in clini-
cal research and thus impact the ethical discourse on use
of animal experiments in medical research. However, the
human source of the stem cells used to develop organoids
is of importance in this discussion. Similarly, patient or
healthy volunteer-derived cellular therapies that replace
current medications may increase the demand for human
cells and tissues for research and therapies. Depending on
the model and therapy, potential cellular sources include
autologous tissues, placenta, umbilical cord or embryos.
In particular, use of embryonic cells is controversial and
views on this practice vary from protection of the human
embryo leading to absolute prohibition to acceptance of
usage given the potential for reducing human suffering.
Ability to use this kind of cells for clinical research will
depend on the context and relevant legal framework for
that setting. A great step forward has been the generation
of iPSC with properties of embryonic stem cells, which
reduces the demand for embryonic stem cells. With
regard to donor consent, research is needed to explore
how donors perceive use of their cells to develop cellular
therapies and what information and consenting process
they find preferable. Issues of ownership and benefits
from products and potential gains/profit from cell-
derived therapies also require attention. While cell thera-
pies present potential for innovation in care for patients
with organ failure, their efficacy must first be proven in
controlled trials [72]. This raises ethical concerns regard-
ing the balance between risks and benefits for participants
in (first-in-) human trials, patient selection, equality in
access, risk-benefit assessment of treatment options,
information provision, minimal requirements for
informed consent, invasiveness and burden of the treat-
ment, potential for adverse side-effects, long-term follow-
up, and reimbursement. Ethical issues need to be consid-
ered for stem cells donors and participants in trials, as
well as for researchers who may face pressure to publish,
produce or commercialize their discoveries.
Conclusion
Regenerative medicine is a rapidly evolving tool that
will affect the lives of the future organ transplant
patient. Whilst regenerative medicine has the potential
to make traditional organ transplantation redundant,
multiple biological, technical, ethical and medical hur-
dles must be surmounted. Regenerative medicine will
need to move to the forefront of transplantation
research in the years to come to make its promises a
reality.
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